LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
← catalyst calendarNCT07288398 · readout in 681 d
Sponsored by Tenax Therapeutics, Inc. (industry) · TENX — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
540estimated
Sites
141
Countries
Argentina, Austria, Brazil +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-03 | actual | When the study began enrolling |
| Primary completion | 2028-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Hypertension Associated With HFpEF
Interventions
- Drug: TNX-103
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OF6-Minute Walk Distance (6MWD)
measured 26 weeks
Permalink · TENX's whole pipeline · Catalyst calendar · Every registered study · What changed